Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD
V-Mono demonstrates for the first time that in patients not receiving lipid-lowering therapy, inclisiran as monotherapy, is superior to both placebo and ezetimibe in reducing LDL-C levels over a 6-month follow-up period and was well tolerated. These findings are consistent with previous observations in statin-treated patients. (Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy [VICTORION-Mono]; NCT05763875).
Authors
- Donavon Wewers
- Edward Cantu (ORCID: https://orcid.org/0000-0003-1105-0129)
- Alexis Gutierrez (ORCID: https://orcid.org/0000-0001-7831-485X)
- Jorge Mena-Madrazo (ORCID: https://orcid.org/0000-0002-9759-708X)
- Catrin Deck
- R. Scott Wright (ORCID: https://orcid.org/0000-0002-0625-0444)
- Anastasia Lesogor
- DJ Ott
- Pam R. Taub (ORCID: https://orcid.org/0000-0002-0684-0655)
- Xiao Zang
- Hui Cao
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- Novartis (Switzerland) (CH)
- Mayo Clinic (US)
- University of San Diego (US)
- University of California San Diego (US)
- Novartis (United States) (US)
- Mayo Clinic in Arizona (US)
- Medical Research Associates (US)
- Mayo Clinic in Florida (US)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1016/j.jacc.2025.04.049
- Citations
- 10
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 16.68
Funders
- Novartis Animal Health